.png)
Your co-pilot for clinical monitoring
Medable’s CRA Agent is an AI-driven solution that automates and optimizes clinical trial monitoring by proactively identifying and prioritizing site risks, generating comprehensive pre-visit summaries, and providing actionable recommendations to enhance trial oversight and compliance.
We estimate that CRA agents can take on up to 90% of the tactical and administrative work the CRA handles on a daily basis — from sending site-specific emails and reminders to tracking responses and updating systems. That means we can focus our time on the strategic decisions that move trials forward, while standardizing and streamlining the tasks that used to consume most of our day.
Connected monitoring across systems
The CRA Agent perceives signals across the entire clinical data ecosystem, unifying CTMS, RTSM, EDC, labs, consent, and safety into one view. It transforms manual checks into automated insights, instantly highlighting which sites are on track and where intervention is needed, saving valuable time, system-hopping and manual data compilation.
Human-in-the-loop oversight
With all data in one place, the CRA Agent plans by identifying risks and recommending best-next actions tied to protocol, consent, and regulatory requirements. A transparent reasoning trail shows why each step is advised, so CRAs can collaborate confidently with sites, improving decision-making, enhancing compliance, and freeing CRAs to focus on engagement and site-specific challenges.
Automated administrative tasks
The CRA Agent acts by executing routine tasks such as drafting queries, sending emails, updating CTMS/eTMF — always with CRA oversight. Automated reminders and real-time tracking close the loop between planning and execution, reducing administrative burden, ensuring data consistency, and accelerating steady trial progress.
The latest from Knowledge Centers
Six steps to help you choose the right clinical trial partner
“This year, we’ve decided to stick to paper. We know what we’re getting and we’ve always done it this way.”
That was the unwavering response from a clinical operations lead at a pioneering biotech when asked why they still relied on paper diaries for patient-reported outcomes.
Despite the growing complexity of global trials, the promise of real-time data, and the surge of digital capabilities available today, some organizations have held tight to a method of clinical trial conduct that’s increasingly as outclassed as it is outdated.
It’s well known that individuals and organizations believe that change can be daunting, stressful, and difficult, especially when the old way is familiar and entrenched. However, much like anything else, having a partner who can help guide you through the process is massively important. But, how do you find the right partner for your trials?
Before locking in a vendor, organizations must engage in a deliberate process to assess their needs, align stakeholders, and set the foundation for long-term success. This blog explores the critical steps sponsors should take before selecting a digital partner, using insights and frameworks drawn from Medable’s therapeutic area standards and industry best practices.
Rewriting the Future of Clinical Trials: AI, Agility, and the Portfolio-First Mandate
In a rapidly changing research landscape, leaders at Takeda, Novartis, Sanofi, Daiichi Sankyo, and Medable share firsthand insights into how artificial intelligence is reshaping clinical trial operations.
This exclusive whitepaper explores how forward-thinking organizations are reimagining trial design, execution, and scaling to meet the demands of speed, precision, and patient-centricity across their entire portfolio.
From bottlenecks to breakthroughs: How AI is transforming translation timelines
According to ClinicalTrials.gov, there are 3,046 multi-country trials being conducted this year. While many trials remain localized within a single country, there has been a definitive movement towards conducting trials in multiple countries, especially for larger, later-stage trials. This is driven by the positives that multi-country trials offer, like faster patient recruitment, lower costs in some regions, and the need for diverse patient populations.. However, behind the scenes, a critical bottleneck has been slowing many trials down. This bottleneck is the translation process that’s required to make trials work across multiple languages, locales, and regulatory bodies/organizations.